B+
Bull case
25%
Probability
Target price
$0.95
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
DYAI
Dyadic InternationalANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$0.59
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$0.31
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-09
Recent news sentiment (30D)
+0.6
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+96.8
Score
AI commentary
Recent coverage is concentrated around the Q2 commercialization update and earnings-call summaries, with generally constructive headline tone but limited independent verification. Social, options, short-interest, employee-rating, and reliable post-print market-reaction data are unavailable; zero values above represent unavailable data rather than neutral evidence. The positive deterministic prior is tempered by financing risk, low coverage, and uncertain conversion of pilot activity into recurring revenue.
RankAlpha Sentiment Codex - 2026-09-09
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-11-30eventConversion of initial commercialization into repeat ordersHigh impact
Q2 disclosures cited shipments of six recombinant protein products after quarter-end, initial pilot sales of transferrin and growth factors, IBT distribution shipments, and initial commercial activity with Fermbox Bio and Inzymes. Revenue was $961,138, down 0.6% year over year, so repeat or larger-volume purchasing remains the key validation point [#SEC-8K-2026-08-12].
2026-11-30catalystFinancing and dilution uncertaintyHigh impact
Cash, restricted cash and investment-grade securities were approximately $4.8 million at June 30, 2026 versus $8.6 million at year-end. An August 14 filing said a registered offering and concurrent private placement were expected to close around that date, but final proceeds, completion, and dilution are not confirmed in the packet [#SEC-8K-2026-08-12] [#8-K-2026-08-14].
2027-09-01catalystPartner-led royalty and pipeline monetizationHigh impact
Proliant began commercializing Albufree DX, BRIG BIO initiated funded scale-up work for recombinant bovine alpha-lactalbumin, and Dyadic continued Gates-, CEPI/FBS-, and other partner-supported biologics programs. These could generate royalties, milestones, licensing, or future clinical value, but timing and scale remain uncertain [#SEC-8K-2026-08-12].
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-09 • Updated nightlySource: Internal modelMethodology